newsfilter
← Latest News
GlobeNewswire·

Xenon Reports Q3 2026 Financial Results and Provides Business Update

  • Xenon Pharmaceuticals submitted a New Drug Application for azetukalner in focal seizures to the FDA in September 2026.
  • Phase 3 X-TOLE3 (focal seizures) & X-ACKT (primary generalized tonic-clonic seizures) studies for azetukalner continue enrollment to support global regulatory submissions.
  • Phase 3b/4 X-FIRST study evaluating azetukalner as first add-on therapy for focal seizures is planned for Q1 2027 initiation.
  • Enrollment in Phase 3 X-NOVA2 study for azetukalner in major depressive disorder completed with topline data expected in December 2026.
  • Positive Phase 1 data for non-opioid pain candidates XEN1701 (Na V 1.7) & XEN1120 (K V 7) presented at IASP 2026 supports Phase 2 proof-of-concept studies in acute pain expected in H1 2027.
  • Cash, cash equivalents & marketable securities totaled $1.2 billion as of September 30, 2026, providing a cash runway into 2029.
  • Research & development expenses were $95.6 million for Q3 2026, driven by azetukalner programs & pain candidates.
  • General & administrative expenses were $24.4 million for Q3 2026 due to increased headcount & professional fees.
  • Net loss was $110.4 million for Q3 2026 compared to $90.9 million in the same period in 2025.
  • Xenon will host a conference call at 4:30 pm EST on November 9, 2026, to discuss Q3 results.
Company
Xenon Pharmaceuticals Inc.
Keywords
Nasdaq:XENE, Xenon Pharmaceuticals Inc., BIOTECHNOLOGY, CONFERENCE CALL, EARNINGS, epilepsy